PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

Company Overview

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 9.65 million shs
• Average Volume: 848,888 shs
• Market Capitalization: $3.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PhaseBio Pharmaceuticals Stock Analysis - MarketRank™

PhaseBio Pharmaceuticals scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for PhaseBio Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PhaseBio Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PhaseBio Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PHAS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PhaseBio Pharmaceuticals does not currently pay a dividend.

Dividend Growth

PhaseBio Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -0.91

Short Interest

There is no current short interest data available for PHAS.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for PhaseBio Pharmaceuticals this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PhaseBio Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.90% of the stock of PhaseBio Pharmaceuticals is held by insiders.

Percentage Held by Institutions

49.02% of the stock of PhaseBio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PHAS Stock Analysis - Frequently Asked Questions

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million.

When did PhaseBio Pharmaceuticals IPO?

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an IPO on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 2/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHAS
• CUSIP: N/A
• CIK: 1169245
• Web: www.phasebio.com
• Phone: (610) 981-6500
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-131,070,000.00
• Net Margins: -12,572.13%
• Pretax Margin: -12,572.13%
• Return on Equity: N/A
• Return on Assets: -174.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.47
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $818,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.93) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 49,858,000
• Free Float: 44,922,000
• Market Cap: $3.50 million
• Optionable: Not Optionable
• Beta: 2.57